The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summarises the modi®cations observed in tumours and discusses the importance of a new family of low af®nity IGF-binding proteins. Further studies on the IGF network will enrich our understanding of prostate tumourigenesis and its control and therefore provide new therapeutics to master the IGF network
New research approaches in cancer research offer the opportunity to underline the role of the Insulin-like Growth Factor (IGF) network as a tool for the prevention of prostate cancer (PCa) as well as a target for its treatment. The IGF system has also a part in the aetiology of Benign Prostate Hyperplasia (BPH), hence emphasising its importance in several prostate pathologies.
The IGF network 1,2 includes two growth factors, four transmembrane receptors, six IGF binding proteins (IGFBP), at least ®ve related-IGFBP, currently one IGFBP receptor and some IGFBP proteases ( Table 1 ). The liver is the main source of IGFs, but most organs also produce them where they are involved in autocrineaparacrine actions. Biological actions of IGFs are mainly mediated by the IGF-IR, which is a tyrosine kinase receptor. The IGF-IIRaMan6P is involved in the traf®cking of lysosomal enzymes but has no known IGF signalling function. Binding of IGF by the insulin receptor or the hybrid IGFainsulin receptor has only been demonstrated in vitro. IGFBPs can act as an IGF-carrier in the blood stream as in the interstitial tissues. In serum, IGFs circulate as a complex that consists of IGF, IGFBP-3 and a non-IGF binding component. IGFBPs extend the half-lives of IGFs, regulate their metabolic clearance, provide a means of tissue-and cell type-speci®c localisation, and modulate IGFs' interactions with their receptors in both positive (IGFBP-5) and negative ways (IGFBP-2, -4). Moreover, IGFPBs can directly affect cellular functions by interacting with a speci®c membrane receptor 3 (for IGFBP-3), by an intrinsic activity, or by their degradation products 2,4 (of IGFBP-3 and -5). IGFBPs proteases, such as Matrix Metalloproteinases (MMPs), participate in IGFs availability. 5 It is worth noticing that their inhibitors, the Tissue Inhibitors of Matrix Metalloproteinases (TIMPs) are also involved in the IGF availability. There is some evidence for a connection between the IGF network and the MMPsaTIMPs system, which is clearly involved in tumour spreading. 6 The IGF system is therefore a very complex interacting network where a single modi®cation in the expression, or the activity, of one of its components can trigger a chain reaction and lead, or at least participate, in the aetiology of the tumourigenic process.
What is the situation in the human prostate? 7 The prostate gland is composed of two main cellular compartments, the stroma, involved in the establishment and maintenance of organ architecture, and the epithelium, responsible for glandular secretion. Growth and development of the prostate depends on androgen action. Androgens act directly by speci®c nuclear receptors and induce or control many effects mediated by peptide growth factors on both epithelial and stromal cells. These peptide growth factors are produced by both cell types and regulate the growth and development of these two cellular compartments by autocrine and paracrine pathways. Several peptide growth factors have been involved in the epithelium-stromal interactions, such as EGF, TGFb, acidic and basic FGF, as well as the IGFs. Cellular and molecular studies have been performed using primary prostate cell cultures or cell lines, as well as tissues samples. Normal prostate cells secrete IGF-II, express the IGF-IR and express a speci®c pattern of IGFBPs. IGFs are involved in cell growth and differentiation in the prostate and also interact with other growth factors such as EGF. In the two main prostate pathologies, adenocarcinoma and benign hyperplasia, the IGF network is the object of modi®cations ( Figure 1 ).
In prostate cancer tissues, a regional loss of imprinting of the IGF-II gene has been demonstrated. 8 In most tissues, the IGF-II gene demonstrates imprinting, being expressed exclusively from the paternal allele. A loss of imprinting results in the biallelic expression of the gene. Some differences in the level of expression of the different IGFBPs have also been evidenced. But the most interesting feature is an increase in the serum level of IGF-I. 9, 10 Increased serum level of IGFBP-2 and decreased IGFBP-3 has also been observed. 11 The latter is possibly related to an increase in PSA level and to the disorganisation of the gland architecture occurring during cancer. PSA, which is normally secreted, can be released inside the gland where it might act as an IGFBPs protease, increasing the avail- Figure 1 IGF network in the human prostate. The prostate gland is mainly composed of stromal cells surrounding epithelial cells. The former are involved in the organ architecture and the latter are responsible for the prostate secretion. IGF is one of the peptide growth factors involved in prostate growth and development. IGF-I is carried in the blood stream mainly associated to the IGFBP-3 plus an Acido Labile Subunit (A). In the normal prostate gland, stromal and epithelial cells produce IGF-II, express the IGF-IR and express a speci®c pattern of IGFBP (B) that controls the availability of the IGFs. Release of IGF by IGFBPs can be increased after degradation by proteases such as MMPs (C). IGFBPs fragments can have their own effects on cell proliferation. The IGFs act through a tyrosine kinase membrane receptor (D). The binding of IGF to its receptor can be enhanced by some IGFBPs (E).
In prostate cancer, serum IGF-I level has been identi®ed as a predictor of prostate cancer risk. Serum IGFBP-2 is increased and serum IGFBP-3 is decreased. PSA might be released into the gland and participate in the degradation of IGFBPs, increasing the total amount of IGF available (F). Protease expression is modi®ed, such as MMP-2 and -9, which are overexpressed and so more able to cleave IGFBPs. A regional loss of imprinting of the IGF-II gene has been observed (G), but without any overproduction of the growth factor. In BPH, IGF-II as well as IGF-IR are overexpressed by the stromal compartment. Stromal cell also express the IGFBP-5, not normally produced. IGFBP-5 is able to bind to the cell membrane and enhances the IGFs action (H). In both cases a different pattern of IGFBPs is observed when compared to normal tissue, leading to a different level of IGFs into the prostate.
New approaches in the prevention and cure of prostate cancer involve the control of circulating IGF (1), the development of molecules able to diminish or cut the production of the IGF network components such as antisense or ribozymes (2), speci®c synthetic inhibitors of the IGFBP proteases (3), and the development of IGFs analogues (4). ability of the IGF. 12 In a similar manner, cathepsin D, MMP-9 and MMP-2 are overexpressed, while TIMP-1 is underexpressed. 13, 14 Most of these modi®cations correlate with the tumour grading and have often been proposed as tumours markers. In BPH, the IGF-IR is overexpressed by the stromal prostate cells, which also overproduce the IGF-II. Interestingly, the stromal cells express the IGFBP-5, which can bind to the cell membrane and potentiates the IGF actions. The tissue level of IGFBP-2 is also decreased. 15 The recently characterised low af®nity IGF binding proteins open a new area of research in prostate pathologies. The members of this subgroup of IGFBPs, also termed CNN family, 16 in regard to its three ®rst members, or IGFBP-related-proteins 17 (IGFBPs-rP) are the CTGF (Connective-Tissues Growth Factor), CyrH61, novH (Nephroblastoma OVerexpressed), and the recently characterised Elm1 18 (expressed in low metastatic mouse cells). The assignation of the Mac25aIGFBP-7/rP1 to the high or the low af®nity IGFBPs is not clearly established.
The comparative analysis of their primary structure has established that they are mosaic proteins which contain 38 conserved cysteine residues and four structural motifs: (1) an IGFBP module; (2) a Von Willebrand Type C module likely to be involved in the formation of oligomeric proteins (proteins formed of two or more polypeptides); (3) a Thrombospondin (type 1 repeat) module thought to be involved in the interaction with extracellular matrix molecules; and (4) a carboxy-terminal motif proposed to represent a dimerisation domain. The functionality of these domains remains to be experimentally con®rmed. Other candidate proteins have been identi®ed by sequence-similarity analysis. 19 Nevertheless, the primary function of these proteins is not to bind IGF but mostly to interact with the extracellular matrix or the cell membrane to regulate in both positive and negative ways the action of other growth factors, such as the case of basic FGF and TGFb by Cyr61. CTGF has been identi®ed as a major chemotactic and mitogenic factor for connective tissue cells and exhibit platelet derived growth factor (PDGF)Ðrelated biological activities. NOV protein has a growth suppressor activity in ®broblast and its expression seems to be inversely correlated with the one of CyrH61. The Elm1 gene is of particular interest as it was expressed in low-metastatic but not in high-metastatic murine melanoma cells. Their role in prostate tissues has to be determined, and interestingly it has been shown recently that some of them are expressed in prostate tissue. For instance, novH mRNA is differentially expressed by cancer cell lines according to their tumourigenicity 20 and CyrH61, which is localised in the mesenchyme of the benign prostatic tissue, is downregulated in prostate cancer tissues as well as in cancer cell lines. 21 These IGFBP-rP could be important for the coordination of stromal and epithelial cell growth in the prostate.
Taken together these modi®cations, in PCa as well as in BPH, lead to a higher availability of IGF that can participate in tumour development and progression. Implications of these studies for prostate cancer epidemiology, screening, prevention, and new therapeutics are numerous (Figure 1) . The most promising recently published work in this ®eld has demonstrated a strong positive association between IGF-I levels and prostate cancer risk, 9,10 a relation that might be used as a prognosis or progression marker in combination with the use of PSA level. Nevertheless as recently discussed by Cohen, 22 studies on serum IGF-I levels and prostate cancer have to be handled with care. It should be noted that, when determining serum IGF levels, the methodologies, as well as the age of the patients and the Gleason grade interfere strongly with the results. Nevertheless, it appears that patients with prostate cancer show an approximately 8% increase in the serum level of IGF-I. The signi®cance of this association could be that: (1) IGF-I promotes BPH and creates an ascertainment bias for the diagnosis of PCa; (2) serum IGF-I represents a marker of prostatic tissue IGF-I that contributes to PCa development and; (3) serum IGF-I directly contributes to the development of PCa. Moreover, the questions of whether serum IGF-I levels should be used as a screening test for identifying high-risk patients or have implications for men already diagnosed with PCa are still unanswered. Additional studies will shed light on the signi®cance of this association and its implications for prognosis, diagnosis and treatment. Other serum and tissue level components of the IGF network have not yet been extensively investigated (such as IGFBP-2) and might provide us with new markers. The interconnection between the IGFs and the MMPs network is also an important area for investigation.
New therapeutics based on the latest progress in emerging preclinical sciences, such as antisense, 23 ribozyme, 24 IGF analogues 25 and synthetic MMPs inhibitors, 26 which have already been proved to reduce the tumourigenic potential of prostate cancer cells and tumours in vitro, can be used to master the IGF network. Some very interesting results have been reported with regards to the IGF axis in other organs or diseases (for review see References 27 and 28) which could greatly impact our view of prostate pathologies. The IGF system is a new door, opening our understanding of prostate tumourigenesis and its control. What is behind it, and how can we make the most of it, is the challenge to be addressed. A lot has to be done but the results are promising.
